Clinical and Molecular Characteristics of Non-Transfusion-Dependent Thalassemia in Kuwait

Hemoglobin

Volumn 39, Issue 5, 2015, Pages 320-326

  Adekile, Adekunle D ^a,b   Azab, Asma F ^b   Al Sharida, Sondus I ^b   Al Nafisi, Bahia A ^c   Akbulut, Nagihan ^d   Marouf, Rajaa A ^a   Mustafa, Nada Y ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b MUBARAK AL KABEER HOSPITAL   (Kuwait)

^c Chest Diseases Hospital Kuwait   (Kuwait)

^d Advanced Technology Company   (Kuwait)

Author keywords

Hb E thalassemia (Hb E thal); Hb H ( 4); Kuwait; non transfusion dependent thalassemia (NTDT); Thalassemia intermedia ( TI)

Indexed keywords

DEFERASIROX; FERRITIN; HEMOGLOBIN BETA CHAIN; HYDROXYUREA; THYROXINE; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN E; HEMOGLOBIN F; HEMOGLOBIN H;

ADOLESCENT; ADULT; ALPHA 2 GLOBIN GENE; ARTICLE; BETA THALASSEMIA INTERMEDIA; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; GALLSTONE; GENE MUTATION; GLOBIN GENE; HEMOGLOBIN E-BETA THALASSEMIA; HEMOGLOBIN H DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPOTHYROIDISM; IRON OVERLOAD; KUWAIT; KUWAITI; LIVER; MALE; MOYAMOYA DISEASE; NON TRANSFUSION DEPENDENT THALASSEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYADENYLATION; PRESCHOOL CHILD; SCHOOL CHILD; THALASSEMIA; THALASSEMIA INTERMEDIA; YOUNG ADULT; BLOOD; GENETICS; MEAN CORPUSCULAR VOLUME; METABOLISM; MUTATION;

ADOLESCENT; ADULT; ALPHA-GLOBINS; BETA-GLOBINS; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE INDICES; FEMALE; FETAL HEMOGLOBIN; HEMOGLOBIN E; HEMOGLOBIN H; HUMANS; KUWAIT; MALE; MUTATION; THALASSEMIA; YOUNG ADULT;

EID: 84940740179     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2015.1053489     Document Type: Article

References (44)

1. th ed. Oxford, UK: Blackwell Science, 2001.
2. Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S3-S6.
3. Galanello R. Recent advances in the molecular understanding of non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S7-S11.
4. Thein SL. The emerging role of fetal hemoglobin induction in nontransfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S35-S39.
5. Higgs DR. The molecular basis of α-thalassemia. Cold Spring Harb Perspect Med. 2013;3(1):a011718. doi: 10.1101/cshperspect.a011718.
6. Chui DHK. α-Thalassaemia and population health in Southeast Asia. Ann Hum Biol. 2005;32(2):123-130.
7. Fucharoen S, Winichagoon P. Haemoglobinopathies in southeast Asia. Indian J Med Res. 2011;134(4):498-506.
8. Olivieri NF, Pakbaz Z, Vichinsky E. Hb E/β-thalassaemia: A common and clinically diverse disorder. Indian J Med Res. 2011;134(4):522-531.
9. 0 thalassemia can present with normal phenotype. Asian J Transfus Sci. 2010;4(2):134-135.
10. Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: A clinical perspective. Blood Rev. 2012;26(Suppl 1):S16-S19.
11. Taher AT, Cappellini MD, Musallam KM. Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S1-S2.
12. Taher AT, Porter JB, Viprakasit V, et al. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: The safety profile of deferasirox. Eur J Haematol. 2014;92(6):521-526.
13. Matta BN, Musallam KM, Maakaron JE, et al. A killer revealed: 10-year experience with β-thalassemia intermedia. Hematology. 2014;19(4):196-198.
14. Taher AT, Temraz S, Cappellini MD. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. Expert Rev Hematol. 2013;6(5):495-509.
15. Shammas C, Papasavva T, Felekis X, et al. ThalassoChip, an array mutation and single nucleotide polymorphism detection tool for the diagnosis of β-thalassaemia. Clin Chem Lab Med. 2010;48(12):1713-1718.
16. Baysal E, Huisman THJ. Detection of common deletional α-thalassemia-2 determinants by PCR. Am J Hematol. 1994;46(3):208-213.
17. S haplotype and α-globin gene patterns among sickle cell anemia patients in Kuwait. Acta Haematol. 1996;96(3):150-154.
18. Tanner MA, He T, Westwood MA, et al. Multi-center validation of the transferability of the magnetic resonance T2∗ technique for the quantification of tissue iron. Haematologica. 2006; 91(10):1388-1391.
19. Hankins JS, McCarville MB, Loeffler RB, et al. R2∗ magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009;113(20):4853-4855.
20. Abu-Hakima A. History of Eastern Arabia 1750-1800: The rise and development of Bahrain, Kuwait and Wahhabi Saudi Arabia. London, UK: Probsthain, 1965.
21. Abdulwahid DA, Hassan MK. β- And α-thalassemia intermedia in Basra, Southern Iraq. Hemoglobin. 2013;37(6):553-563.
22. Adekile AD, Haider M, Kutlar F. Mutations associated with β-thalassemia intermedia in Kuwait. Med Princ Pract. 2005;14(Suppl 1):69-72.
23. Al-Allawi NA, Jalal SD, Mohammad AM, et al. β-Thalassemia intermedia in Northern Iraq: A single center experience. BioMed Res Int. 2014;2014:262853. doi: 10.1155/2014/262853.
24. Ankra-Badu GA, Al-Jama A, Al Kadim Y. Hemoglobin H disease in the Al-Qatif Region of Saudi Arabia. Ann Saudi Med. 2001;21(5-6):308-311.
25. Haider M. Adekile AD: α2-Globin gene polyadenylation (AATAAA→AATAAG) mutation in Hemoglobin H disease among Kuwaitis. Med Princ Pract. 2005;14(Suppl 1):73-76.
26. Wali Y, Zadjali SA, Elshinawy M, et al. Severity ranking of nondeletional α thalassemic alleles: Insights from an Omani family study. Eur J Haematol. 2011;86(6):507-511.
27. Higgs DR, Goodbourn SE, Lamb J, et al. α-Thalassaemia caused by a polyadenylation signal mutation. Nature. 1983;306(5941):398-400.
28. Thein SL, Wallace RB, Pressley L, et al. The polyadenylation site mutation in the a-globin gene cluster. Blood. 1988;71(2):313-319.
29. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica. 2013;98(6):833-844.
30. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-4433.
31. Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program. 2011;2011:538-542. doi: 10.1182/asheducation-2011.1.538.
32. Taher AT, Viprakasit V, Musallam KM. Cappellini MD. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol. 2013;88(5):409-415.
33. Cappellini MD, Musallam KM, Poggiali E, Taher AT. Hypercoagulability in non-transfusion-dependent thalassemia. Blood Rev. 2012;26(1):S20-S23.
34. Karimi M, Musallam KM, Cappellini MD, et al. Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. Eur J Int Med. 2011;22(6):607-610.
35. Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96(4):488-491.
36. Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in β-thalassemia intermedia: Breaking the silence. Thromb Res. 2012;130(5):695-702.
37. Musallam KM, Cappellini MD, Daar S, et al. Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: The ORIENT study. Haematologica. 2014; 99(11):e218-e221.
38. Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol. 2010;150(4):486-489.
39. Cappellini MD, Musallam KM, Taher AT. Insight onto the pathophysiology and clinical complications of thalassemia intermedia. Hemoglobin. 2009;33(Suppl 1):S145-S159.
40. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: Revisited. Blood Cells Mol Dis. 2006;37(1):12-20.
41. Au WY, Cheung WC, Hu WH, et al. Hyperbilirubinemia and cholelithiasis in Chinese patients with Hemoglobin H disease. Ann Hematol. 2005;84(10):671-674.
42. Premawardhena A, Fisher CA, Fathiu F, et al. Genetic determinants of jaundice and gallstones in Haemoglobin E β thalassaemia. Lancet. 2001;357(9272):1945-1946.
43. Musallam KM, Sankaran VG, Cappellini MD, et al. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood. 2012;119(2):364-367.
44. Kosaryan M, Karami H, Zafari M, Yaghobi N. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. Hemoglobin. 2014;38(2):115-118.